Piramal Imaging Sa

Bayer Aktiengesellschaft

Hoechst Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Bayer Schering Pharma Ag

A.n. Nesmeyanov Institute of Organoelement Compounds the Russian Academy of Sciences

N. P. Bechtereva Institute of the Human Brain of the Russian Academy of Sciences

Lutz Lehmann

Johannes Platzek

Heribert Schmitt-Willich

Markus Follmann

Thomas Brumby

Tobias Heinrich

Christer Halldin

Sangram Nag

Keith Graham

Mathias Berndt

Georg Kettschau

Timo Stellfeld

Matthias Friebe

Andre Müller

Adrian Tersteegen

Alexandros Vakalopoulos

Alexander Hillisch

Lars Bärfacker

Christoph Gerdes

Stefan Heitmeier

Anja Buchmüller

Detlev Sülzle

Hartmut Beck

Martin Kruger

Gerd Heppke

Simon Mensah Ametamey

Gunter Scherowsky

Kersten Matthias Gericke

Ludger Dinkelborg

Detlev Suelzle

Jorma Haβfeld

Frank Süssmeier

Balazs Gulyas

Andrea Thiele

Niels Böhnke

Christian Bahr

Yuri Belokon

Norman Koglin

Sonja Vollmer

Guillaume Levilain

Andrea Varrone

Frank Süßmeier

Julia Dietze-Torres

Stefanie Mesch

Nils Pfaff

Stefanie Zimmermann

Elisabeth Kersten

Andreas Peter Broehl

Nikolaevna Raisa Krasikowa

Axel Rother

Fedorovna Olga Kuznetsova

Mylene Tania Karramkam

Detlef Suelzle

Ananth Srinivasan

Kartrin Partikel

Myléne Karramkam

Balazs GULYÁS

Olga Fedorovna Kuznetsova

Raisa Nikolaevna Krasikowa

Stephan Siegel

Katrin Partikel

The invention relates to substituted S-alaninate derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications.

Substituted S-alaninate derivatives

This invention relates to novel compounds suitable for labelling or already labelled byF, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).

Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors

The compounds and the synthesis of [F-18]-labeled L-glutamic acid, [F-18]-labeled L-glutamate, their derivatives as set forth in formula (I) and their uses are described.

[F-18]-labeled L-glutamic acid, [F-18]-labeled L-glutamine, derivatives thereof and use thereof and processes for their preparation

This invention relates to novel compounds suitable as precursors for the preparation of certainF labelled positron emission tomography (PET) tracers. Furthermore the invention relates to the preparation of such precursor molecules and to the preparation of PET tracers byF labelling of such precursors.

Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system

This invention relates to novel compounds suitable for labeling byF and to the correspondingF labeled compounds themselves,F-fluorinated analogs thereof and their use as reference standards, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by Positron Emission Tomography (PET).

Radiolabeled amino acids for diagnostic imaging

This invention relates to homoglutamic acid derivatives suitable for labeling or already labeled withF orF, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging.

Homoglutamic acid derivatives

This invention relates to novel compounds suitable for labeling or already labeled byF, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).

The present invention relates to novel compounds suitable for or already radiolabeled withF, methods of making such compounds and use of such compounds for diagnostic imaging. Such labeled compounds are characterized by Formula II, wherein the substituents G, Q, L, Y and U have the meaning as defined in the specification and claims. 

[object Object]

The present invention relates to phenyloxyaniline derivatives, to methods of their production and to uses thereof.

Phenyloxyaniline derivatives

The novel compounds are chiral esters of .alpha.-substituted phenylalkanoic acids and mesogenic hydroxy compounds, the symbols in the general formula (I) ##STR1## being defined as follows: MO=molecular radical of a mesogenic hydroxy compound MOH after removal of one H, the radical MO being expressed by the general formula (II)

Chiral esters of .alpha.-substituted phenylalkanoic acids and mesogenic

Growing community of inventors

Berlin, Germany

Lutz Lehmann